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Dopamine and cAMP regulated phosphoprotein 32 kDa (DARPP-32) also known as phosphoprotein 
phosphatase-1 regulatory subunit 1B and encoded by the PPP1R1B gene is an inhibitor of protein 
phosphatase-1 and protein kinase A. DARPP-32 is expressed in a wide range of epithelial cells and some 
solid tumours; however, its role in breast cancer is only partially defined. DARPP-32 expression was 
determined using immunohistochemistry in two independent cohorts of early stage invasive breast 
cancer patients (discovery n = 1352; validation n = 1655), and 112 HER2 positive breast cancer patients 
treated with trastuzumab and adjuvant chemotherapy. PPP1R1B mRnA expression was assessed in 
the METABRIC cohort (n = 1980), using artificial neural network analysis to identify associated genes. 
In the discovery cohort, low nuclear expression of DARPP-32 was significantly associated with shorter 
survival (P = 0.041), which was independent of other prognostic variables (P = 0.019). In the validation 
cohort, low cytoplasmic and nuclear expression was significantly associated with shorter survival (both 
P = 0.002), with cytoplasmic expression independent of other prognostic variables (P = 0.023). Stronger 
associations with survival in oestrogen receptor (ER) positive disease were observed. In patients treated 
with trastuzumab, low nuclear expression was significantly associated with adverse progression-free 
survival (P = 0.031). In the METABRIC cohort, low PPP1R1B expression was associated with shortened 
survival of eR positive patients. expression of CDC42 and GRB7, amongst others, were associated with 
PPP1R1B expression. This data suggests a role for DARPP-32 as a prognostic marker with clinical utility 
in breast cancer.
Dopamine and cAMP regulated phosphoprotein 32 kDa (DARPP-32) also known as phosphoprotein 
phosphatase-1 regulatory subunit 1B and encoded by the PPP1R1B gene, was first described in 19831 and has 
been widely characterised as a signalling protein highly concentrated in brain regions rich in dopaminergic nerve 
terminals2–4. DARPP-32 was originally demonstrated to be a potent inhibitor of protein phosphatase-1 (PP-1) 
and a substrate of calcineurin5,6. Protein kinase A (PKA) phosphorylation of Thr34 allows DARPP-32 to inhibit 
protein phosphatase-1 (PP-1); cyclin dependent kinase (CDK)-5 phosphorylation of Thr75 allows DARPP-32 to 
inhibit PKA and enhance β-adducin Ser713 phosphorylation7. A truncated DARPP-32 isoform, t-DARPP, lacks 
the Thr-34 phosphorylation site and was originally identified in gastric cancer8. Interaction between DARPP-32, 
calcineurin and Bcl-2 assists with the anti-apoptotic function of Bcl-2 by preventing Ca2+ induced cell death 
through interaction with inositol 1,4,5-triphosphate receptor (InsP3R)9.
1Nottingham Breast Cancer Research Centre, Division of Cancer and Stem Cells, School of Medicine, University of 
Nottingham, Nottingham City Hospital, Nottingham, NG5 1PB, UK. 2John van Geest Cancer Research Centre, School 
of Science and Technology, Nottingham Trent University, Clifton Campus, Nottingham, NG1 4BU, UK. *email: sarah.
storr@nottingham.ac.uk
open
2Scientific RepoRtS |         (2019) 9:16987  | https://doi.org/10.1038/s41598-019-53529-z
www.nature.com/scientificreportswww.nature.com/scientificreports/
DARPP-32 activation is regulated by an array of neurotransmitters, such as dopamine, glutamate, serotonin 
and adenosine, but has also been shown to mediate the actions of multiple drugs of abuse, including cocaine, 
amphetamine, nicotine and caffeine (reviewed in10). DARPP-32 has been implicated in a number of psychiat-
ric and neurological disorders, such as schizophrenia. In addition to the central nervous system, DARPP-32 is 
expressed in a wide range of epithelial cells11.
High levels of DARPP-32 in colorectal cancer are associated with survival of Dukes A and B patients12, 
and in glioblastoma, high DARPP-32/STAT3 and DARPP-32/STAT5B mRNA ratios are associated with 
longer progression free survival and overall survival13. In gastric cancer, DARPP-32 can promote cell inva-
sion through CXCR4-mediated activation of the MT1-MMP/MMP-2 pathway14. A PPP1R1B-STARD3 
fusion transcript has also been identified in gastric cancer, that increases in vitro cell proliferation through the 
phosphatidylinositol-3-kinase (PI3K)/AKT pathway15. DARPP-32 has been shown to influence breast epithe-
lial cell migration; in MCF-7 and MDA-MB-231 cells this has been shown to be in a DDR1 dependent man-
ner16. DARPP-32 phosphorylation, induced by Wnt-5a, has also been shown to inhibit MCF-7 cell migration in 
a CREB-dependent manner17.
The truncated splice variant, t-DARPP is present in gastric, breast, prostate, colon and stomach cancers8,11, and 
in models of murine tumourigenesis, DARPP-32 expression is expressed in normal mouse tissue and some breast 
tumours, with t-DARPP expressed only within tumours18. In breast cancer, t-DARPP mRNA is expressed in 36% 
of primary breast cancers (n = 36) relative to adjacent normal breast tissues (n = 18)19. Interestingly, the expres-
sion of t-DARPP has been implicated in resistance to the HER2 targeted agent, trastuzumab, in HER2 positive 
breast cancer cells via sustained signalling through phosphatidylinositol-4,5 bisphosphate 3-kinase (PI3K)/akt 
pathway and activation of PKA in vitro19–23, and in conferring a survival advantage to the HER2 targeted agent, 
lapatinib24. The role of DARPP-32 and t-DARPP in cancer is reviewed in25.
We sought to determine the frequency and importance of DARPP-32 expression in two large independent 
cohorts of early stage invasive breast cancer patients, including an additional cohort of HER2 positive breast can-
cer patients treated with trastuzumab to examine if DARPP-32 was associated with patient survival. In addition 
to protein expression, we sought to assess PPP1R1B mRNA expression in a large, well-annotated series of breast 
cancer patients, including artificial neural network analysis to identify genes associated with PPP1R1B expression.
Methods
patient cohorts. This study is reported according to reporting recommendations for tumour marker prog-
nostic studies (REMARK) criteria26. For protein expression three well-characterised patient cohorts were used; 
the discovery cohort, functioned as a discovery set; the validation cohort, functioned as a validation set and 
the HER2 cohort was used to assess DARPP-32 expression in HER2 positive patients treated with trastuzumab. 
Breast cancer specific survival was calculated as the time interval between primary surgery and death resultant 
from breast cancer. Progression-free survival was defined as the date of surgery to relapse (including local and 
regional relapse).
Discovery cohort. 1352 early stage invasive breast cancer patients were available for assessment in the dis-
covery cohort, with all patients treated at Nottingham University Hospitals between 1987 and 1998. All patients 
were managed in a standard manner, where all patients underwent a mastectomy or wide local excision, as 
decided by disease characteristics or patient choice, followed by radiotherapy if indicated. Patients received 
systemic adjuvant treatment on the basis of Nottingham Prognostic index (NPI), oestrogen receptor (ER), and 
menopausal status. Patients with an NPI score less than 3.4 did not receive adjuvant treatment and patients with 
an NPI score of 3.4 and above were candidates for CMF combination chemotherapy (cyclophosphamide, meth-
otrexate and 5-fluorouracil) if they were ER negative or premenopausal; and hormonal therapy if they were ER 
positive. Median follow-up was 205 months determined using the reverse Kaplan-Meier method and clinico-
pathological information for this cohort is available in Table 1.
Validation cohort. 1655 early stage invasive breast cancer patients were available for assessment in the val-
idation cohort, with all patients treated at Nottingham University Hospitals between 1998 and 2006. All patients 
were managed in a standard manner, as described for the discovery cohort. Median follow-up was 148 months 
determined using the reverse Kaplan-Meier method and clinicopathological information for this cohort is avail-
able in Table 1.
HER2 positive cohort. 112 HER2 positive breast cancer patients were available for assessment in the HER2 
positive cohort, with all patients treated at Nottingham University Hospitals between 2004 and 2012. Patients 
were treated according to local guidelines, with adjuvant therapy and trastuzumab following surgery. Adjuvant 
hormone therapy was received by 47% of patients (40/75), with 74% of patients receiving adjuvant radiotherapy 
(59/80). Trastuzumab was given on a 3-weekly regimen for 52 weeks, with patients receiving trastuzumab fol-
lowing six cycles of 3-weekly FEC chemotherapy (fluorouracil, epirubicin and cyclophosphamide) or patients 
receiving three cycles of FEC, followed by three cycles of taxane (FEC-T), to which, trastuzumab was frequently 
added from the second cycle of taxane onwards. Median follow-up was 50 months determined using the reverse 
Kaplan-Meier method and clinicopathological information for this cohort is available in Table 2.
MetABRic series. Details of the Molecular Taxonomy of Breast Cancer International Consortium 
(METABRIC) data set (n = 1980) data set have been published elsewhere27. Tumours were collected by five cen-
tres in the UK and Canada between 1977–2005 and almost all ER negative and lymph node positive patients 
received adjuvant chemotherapy, whereas ER negative and/or lymph node positive patient did not. No patients 
with HER2 overexpression received trastuzumab. Median follow-up was 141 months determined using the 
reverse Kaplan-Meier method. DNA and RNA were isolated from samples and hybridised to the Affymetrix 
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SNP 6.0 and Illumina HT-12 v3 platforms for genomic and transcriptional profiling as described by Curtis et al. 
(2012)27. This cohort was used to assess the prognostic significance of DARPP-32 at the mRNA level and deter-
mine associations with other genes using artificial neural network analysis.
Discovery cohort Validation cohort
Cytoplasmic expression Nuclear expression Cytoplasmic expression Nuclear expression
Low High P value Low High P value Low High P value Low High P value
Age
<50 years 221 (16.4%) 238 (17.6%)
0.470
295 (21.8%) 164 (12.1%)
0.467
222 (13.5%) 283 (17.3%)
0.881
272 (16.6%) 233 (14.2%)
0.251
≥50 years 448 (33.2%) 444 (32.9%) 591 (43.7%) 301 (22.3%) 494 (30.1%) 640 (39.0%) 576 (35.1%) 558 (34.0%)
Tumour size
<20 mm 414 (30.8%) 397 (29.5%)
0.188
594 (40.8%) 262 (19.5%)
0.052
422 (25.8%) 589 (36.0%)
0.048
513 (31.3%) 334 (20.4%)
0.320
³20 mm 253 (18.8%) 281 (20.9%) 334 (24.8%) 200 (14.9%) 293 (17.9%) 334 (20.4%) 498 (30.4%) 293 (17.9%)
T stage
1 404 (30.0%) 415 (30.9)
0.210
536 (39.9%) 283 (21.0%)
0.500
424 (25.9%) 608 (37.2%)
0.016
501 (30.6%) 531 (32.5%)
0.0012 215 (16.0%) 197 (14.6%) 277 (20.6%) 135 (10.0%) 208 (12.7%) 237 (14.5%) 244 (14.9%) 201 (12.3%)
3 49 (3.6%) 65 (4.8%) 70 (5.2%) 44 (3.3%) 81 (5.0%) 77 (4.7%) 100 (6.1%) 58 (3.5%)
Tumour grade
1 104 (7.7%) 124 (9.2%)
0.165
153 (11.4%) 75 (5.6%)
0.391
84 (5.1%) 179 (10.9%)
<0.001
105 (6.4%) 158 (9.6%)
<0.0012 238 (17.7%) 212 (15.8%) 304 (22.6%) 146 (10.9%) 300 (18.3%) 358 (21.9%) 349 (21.3%) 309 (18.9%)
3 325 (24.2%) 342 (25.4%) 426 (31.7%) 241 (17.9%) 331 (20.2%) 386 (23.6%) 393 (24.0%) 324 (19.8%)
ER status
Negative 132 (10.1%) 216 (16.5%)
<0.001
173 (13.2%) 175 (13.4%)
<0.001
90 (5.5%) 230 (14.0%)
<0.001
114 (7.0%) 206 (12.6%)
<0.001
Positive 518 (39.5%) 444 (33.9%) 683 (52.1%) 279 (21.3%) 626 (38.2%) 694 (42.3%) 734 (44.8%) 586 (35.7%)
PgR status
Negative 247 (19.4%) 301 (23.7%)
0.007
319 (25.1%) 229 (18.0%)
<0.001
246 (15.9%) 405 (26.1%)
<0.001
299 (19.3%) 352 (22.7%)
<0.001
Positive 381 (30.0%) 341 (26.9%) 513 (40.4%) 249 (16.5%) 425 (27.4%) 473 (30.5%) 502 (32.4%) 396 (25.6%)
NPI category
Good (≤3.4) 199 (14.8%) 208 (15.5%)
0.810
275 (20.5%) 132 (9.8%)
0.432
230 (14.1%) 339 (20.7%)
0.002
275 (16.8%) 294 (18.0%)
<0.001Intermediate (3.41–5.4) 348 (25.9%) 342 (25.5%) 452 (33.7%) 238 (17.7%) 347(21.2%) 465 (28.5%) 405 (24.8%) 407 (24.9%)
Poor (>5.4) 119 (8.9%) 127 (9.5%) 154 (11.5%) 92 (6.9%) 135 (8.3%) 118 (7.2%) 164 (10.0%) 89 (5.4%)
Tubule formation
1 31 (2.4%) 44 (3.4%)
0.218
43 (3.3%) 32 (2.5%)
0.160
28 (1.7%) 92 (5.7%)
<0.001
43 (2.6%) 77 (4.7%)
<0.0012 201 (15.5%) 219 (16.9%) 286 (22.1%) 134 (10.3%) 184 (11.3%) 295 (18.2%) 219 (13.5%) 260 (16.0%)
3 408 (31.5%) 394 (30.4%) 519 (40.0%) 283 (21.8%) 494 (30.4%) 531 (32.7%) 573 (35.3%) 452 (27.8%)
Pleomorphism
1 9 (0.7%) 17 (1.3%)
0.179
14 (1.1%) 12 (0.9%)
0.031
5 (0.3%) 19 (1.2%)
0.016
10 (0.6%) 14 (0.9%)
0.0812 267 (20.6%) 252 (19.5%) 360 (27.8%) 159 (12.3%) 200 (12.3%) 294 (18.1%) 236 (14.5%) 258 (15.9%)
3 36 (28.0%) 387 (29.9) 473 (36.5%) 277 (21.4%) 501 (30.8%) 605 (37.3%) 589 (36.3%) 517 (31.8%)
Mitosis
1 213 (16.4%) 239 (18.4%)
0.093
293 (22.6%) 159 (12.3%)
0.241
336 (20.7%) 469 (28.9%)
0.034
392 (24.2%) 413 (25.5%)
0.0072 138 (10.6%) 111 (8.6%) 174 (13.4%) 75 (5.8%) 153 (9.4%) 152 (9.4%) 181 (11.2%) 124 (7.6%)
3 289 (22.3%) 307 (23.7%) 381 (29.4%) 215 (16.6%) 217 (13.4%) 295 (18.2%) 262 (16.2%) 250 (15.4%)
HER2 status
Negative 570 (43.4%) 552 (42.0%)
0.052
762 (58.0%) 360 (27.4%)
<0.001
636 (41.2%) 779 (50.5%)
0.025
750 (48.6%) 665 (43.1%)
0.113
Positive 83 (6.3%) 109 (8.3%) 104 (7.9%) 88 (6.7%) 44 (2.9%) 83 (5.4%) 58 (3.8%) 69 (4.5%)
Triple negative disease
Negative 558 (42.6%) 515 (39.3%)
0.001
734 (56.0%) 339 (25.9%)
<0.001
640 (39.7%) 733 (45.5%)
<0.001
753 (46.7%) 620 (38.5%)
<0.001
Positive 96 (7.3%) 142 (10.8%) 130 (9.9%) 108 (8.2%) 67 (4.2%) 171 (10.6%) 85 (5.3%) 153 (9.5%)
Vascular invasion
Negative 430 (32.2%) 464 (34.7%)
0.141
582 (43.5%) 312 (23.3%)
0.589
481 (29.4%) 678 (41.4)
0.007
568 (34.7%) 591 (36.1%)
<0.001
Positive 232 (17.4%) 211 (15.8%) 295 (22.1%) 148 (11.1%) 233 (14.2%) 245 (15.0%) 278 (17.0%) 200 (12.2%)
Table 1. Associations between the cytoplasmic and nuclear expression of DARPP-32, determined in the 
discovery cohort and validation cohort using immunohistochemistry, with clinicopathological variables. The P 
values are resultant from Pearson χ2 test of association and significant values (P < 0.05) are highlighted in bold. 
ER is oestrogen receptor and PgR is progesterone receptor.
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immunohistochemistry. Immunohistochemistry was performed on tissue microarrays for the discovery 
cohort, validation cohort and the HER2 cohort, and were comprised of single 0.6 mm cores taken from a rep-
resentative tumour area as assessed on Haematoxylin and Eosin stained sections by a specialist breast cancer 
histopathologist. Immunohostochemical staining was achieved using a Novolink Polymer Detection kit (Leica) 
according to the manufacturers’ instructions, the use of which has been described previously28–30. In brief, xylene 
was used to deparaffinise tissue, followed by rehydration in ethanol then water. Antigen retrieval was achieved in 
0.01molL−1 sodium citrate buffer (pH6.0), heated in a microwave for 10 minutes at 750 W followed by 10 minutes 
at 450 W. Tissue was treated with Novolink Peroxidase Block, washed with Tris-buffered saline (TBS), and then 
treated with Novolink Protein Block solution. Rabbit polyclonal anti-DARPP-32 (Abcam ab40801) diluted 1:500 
was used as primary antibody and was incubated on tissue for one hour at room temperature. Antibody specificity 
was confirmed by Western blotting on breast cancer cell lysates prior to use. Tissue was washed with TBS prior to 
the application of Novolink Post Primary solution, which was subsequently washed with TBS and then Novolink 
Polymer solution was applied. Immunohistochemical reactions were developed using 3,3′ diaminobenzidine as 
the chromogenic substrate and tissue was counterstained with haematoxylin. Tissue was dehydrated in ethanol 
and fixed in xylene prior to mounting using DPX. Positive and negative controls were included with each stain-
ing run and were comprised of breast tumour composite sections comprising grade 1 and 2 early stage invasive 
tumour; negative controls had primary antibody omitted from each staining run (Supplementary Information).
Statistical analyses. Slides were scanned using a Nanozoomer Digital Pathology Scanner (Hamamatsu 
Photonics) and staining was assessed at 200x magnification. Staining in the cytoplasm was assessed using a 
semi-quantitative immunohistochemical H score, where staining intensity within tumour cells was assessed as 
none (0), weak (1), medium (2) or strong (3) over the percentage area of each staining intensity. Staining in the 
nucleus was examined in a semi-quantitative manner, where the percentage of tumour cells that demonstrated 
any staining intensity was assessed. Greater than 30% of cores for each TMA were double assessed, with both 
assessors blinded to clinical outcome and each other’s scores. Single measure intraclass correlation coefficients 
were above 0.7, indicating good concordance between scorers.
Statistical analysis was performed using IBM SPSS Statistics (version 24). Cases were stratified based on 
breast cancer specific survival for both the discovery and validation cohorts and the METABRIC cohort, and 
relapse-free survival for the HER2 positive cohort, using X-Tile software31. All differences were deemed statisti-
cally significant at the level of P ≤ 0.05. The Pearson χ2 test of association was used to determine the relationship 
between categorised protein expression and clinicopathological variables. Survival curves were plotted according 
to the Kaplan-Meier method with significance determined using the log-rank test.
Identification of genes associated with DARPP-32 expression. A supervised artificial neural net-
work was used to further understand the molecular function of PPP1R1B in breast cancer in the METABRIC 
Cytoplasmic Nuclear
Low High P value Low High P value
Age
≤40 years 6 (5.4%) 9 (8.0%)
0.710
6 (5.4%) 9 (8.0%)
0.651
>40 years 34 (30.4%) 63 (56.3%) 33 (29.5%) 64 (57.1%)
Tumour size
≤20 mm 24 (21.6%) 44 (39.6%)
0.965
24 (21.6%) 44 (39.6%)
0.767
>20 mm 15 (13.5%) 28 (25.2%) 14 (12.6%) 29 (26.1%)
Node status
Negative 16 (14.3%) 28 (25.0%)
0.908
15 (13.4%) 29 (25.9%)
0.896
Positive 24 (21.4%) 44 (39.3%) 24 (21.4%) 44 (39.3%)
T stage
0 0 (0.0%) 1 (0.9%)
0.644
0 (0.0%) 1 (0.9%)
0.684
1 25 (22.3%) 44 (39.3%) 25 (22.3%) 44 (39.3%)
2 14 (12.5%) 22 (19.6%) 13 (11.6%) 23 (20.5%)
3 1 (0.9%) 5 (4.5%) 1 (0.9%) 5 (4.5%)
Tumour grade
1 0 (0.0%) 3 (2.7%)
0.424
0 (0.0%) 3 (2.7%)
0.4302 13 (11.6%) 22 (19.6%) 13 (11.6%) 22 (19.6%)
3 27 (24.1%) 47 (42.0%) 26 (23.2%) 48 (42.9%)
ER status
Negative 14 (12.5%) 36 (32.1%)
0.126
14 (12.5%) 36 (32.1%)
0.174
Positive 26 (23.2%) 36 (32.1%) 25 (22.3%) 37 (33.0%)
PgR status
Negative 16 (17.2%) 43 (46.2%)
0.163
16 (17.2%) 43 (46.2%)
0.265
Positive 14 (15.1%) 20 (21.5%) 13 (14.0%) 21 (22.6%)
NPI category
Good (≤3.4) 1 (1.0%) 6 (5.9%)
0.417
2 (2.6%) 5 (5.0%)
0.385Intermediate (3.41–5.4) 27 (26.7%) 42 (41.6%) 23 (22.8%) 46 (45.5%)
Poor (>5.4) 10 (9.9%) 15 (14.9%) 12 (11.9%) 13 (12.9%)
Table 2. Associations between the expression of DARPP-32 determined in HER2 positive breast cancer 
patients treated with trastuzumab and adjuvant chemotherapy and clinicopathological variables. The P values 
are resultant from Pearson χ2 test of association and significant values (P < 0.05) are highlighted in bold. ER is 
oestrogen receptor and PgR is progesterone receptor.
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series. PPP1B1R expression was used as the supervising variable as described by Abdel-Fatah et al.32. The arti-
ficial neural network was conducted with a constrained multi-layer perceptron architecture and sigmoidal 
transfer function, where weights were updated by a feed forward back propagation algorithm. Probes from the 
METABRIC data were ranked based on their root mean squared (RMS) error for predication of DARPP-32 
expression as a continuous variable.
Results
DARPP-32 protein staining location and frequency. DARPP-32 protein expression was assessed in 
two large independent cohorts of early invasive breast cancer. Nuclear and cytoplasmic DARPP-32 expression was 
observed in all cohorts and varied from weak to intense, with heterogeneity observed between adjacent tumour 
cells. Representative photomicrographs are shown in Fig. 1. In the discovery cohort, 1352 patients were assessed, 
cytoplasmic DARPP-32 expression had a median H-score of 40, and ranged from 0 to 300. In the validation 
cohort, 1655 patients were assessed, cytoplasmic DARPP-32 expression had a median H score of 20 and ranged 
from 0 to 300. Nuclear DARPP-32 expression in the discovery cohort had a median H score of 0 and ranged 
Figure 1. Representative photomicrographs DARPP-32 staining. Photomicrographs of low DARPP-32 
immunohistochemical staining (A), and high staining (B) are shown at 100x magnification with 200x 
magnification inset box where the scale bar represents 100 µm. Kaplan-Meier analysis of breast cancer specific 
survival showing the impact of low (grey line) and high (black line) DARPP-32 protein expression within the 
cytoplasm (C) or the nucleus (D) in the discovery cohort, and within the cytoplasm (E) or the nucleus (F) in the 
validation cohort. Significance was determined using the log-rank test. The numbers shown below the Kaplan-
Meier survival curves are the number of patients at risk at the specified month.
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from 0 to 100; in the validation cohort, the median DARPP-32 H-score was 5 and ranged from 0 to 100. X-tile 
was used to generate cut points for use in both cohorts based on breast cancer specific survival. In the discovery 
cohort, cytoplasmic DARPP-32 expression had a cut point of 35, with 49.6% of cases (670/1352) demonstrating 
low expression; in the validation cohort a cut point of 10 was used, with 43.6% of cases (722/1655) demonstrating 
low expression. In the discovery cohort, nuclear DARPP-32 expression had a cut point of 20, with 65.6% of cases 
(887/1352) demonstrating low expression; in the validation cohort, a cut point of 10 was used, with 51.5% of cases 
(853/1655) demonstrating low expression.
Relationship between DARPP-32 protein expression and clinicopathological variables. In 
the discovery cohort, low cytoplasmic DARPP-32 expression was significantly associated with ER and PgR 
positive tumours (χ2 = 25.893, d.f. = 1, P < 0.001 and χ2 = 7.384, d.f. = 1, P = 0.007 respectively) and absence 
of triple negative disease (χ2 = 10.607, d.f. = 1, P = 0.001) (Table 1). In the validation cohort, low cytoplasmic 
DARPP-32 expression was significantly associated with larger tumour size (χ2 = 3.917, d.f. = 1, P = 0.048), 
higher tumour grade (χ2 = 17.517, d.f. = 2, P < 0.001), tubule formation (χ2 = 34.097, d.f. = 2, P < 0.001), pleo-
morphism (χ2 = 3.917, d.f. = 2, P = 0.016), lower mitosis (χ2 = 6.785, d.f. = 2, P = 0.034), increased tumour stage 
(χ2 = 8.215, d.f. = 2, P = 0.016), ER and PgR positive tumours (χ2 = 39.000, d.f. = 1, P < 0.001 and χ2 = 13.987, 
d.f. = 1, P < 0.001 respectively), belonging to a poor NPI prognostic group (χ2 = 12.386, d.f. = 2, P = 0.002) and 
HER2 status (χ2 = 5.017, d.f. = 1, P = 0.025), absence of triple negative disease (χ2 = 28.075, d.f. = 1, P < 0.001), 
and the presence of lymphovascular invasion (χ2 = 7.220, d.f. = 1, P = 0.007) (Table 1).
In the discovery cohort, low nuclear DARPP-32 expression was significantly associated with increased ple-
omorphism (χ2 = 6.943, d.f. = 2, P = 0.031), ER and PgR positive tumours (χ2 = 51.128, d.f. = 1, P < 0.001 and 
χ2 = 22.736, d.f. = 1, P < 0.001 respectively), HER2 negative tumours (χ2 = 13.790, d.f. = 1, P < 0.001), and the 
absence of triple negative disease (χ2 = 16.472, d.f. = 1, P < 0.001) (Table 1). In the validation cohort, low nuclear 
DARPP-32 expression was significantly associated with higher grade tumours (χ2 = 17.859, d.f. = 2, P < 0.001), 
tubule formation (χ2 = 26.145, d.f. = 2, P < 0.001), lower mitosis (χ2 = 10.070, d.f. = 2, P = 0.007), higher 
tumour stage (χ2 = 14.358, d.f. = 2, P = 0.001), ER and PgR positive tumours (χ2 = 41.180, d.f. = 1, P < 0.001 
and χ2 = 15.031, d.f. = 1, P < 0.001 respectively), belonging to a poor NPI prognostic group (χ2 = 21.111, d.f. = 2, 
P < 0.001), the absence of triple negative disease (χ2 = 28.738, d.f. = 1, P < 0.001), and the presence of lympho-
vascular invasion (χ2 = 11.349, d.f. = 1, P = 0.001) (Table 1).
Association between DARPP-32 protein expression and survival. In the discovery cohort, 
low nuclear expression of DARPP-32 was significantly associated with adverse breast cancer specific survival 
(P = 0.041) (Fig. 1D). Low nuclear expression of DARPP-32 remained significantly associated with adverse sur-
vival (hazard ratio (HR): 0.766; 95% confidence interval (CI): 0.613–0.957; P = 0.019) when potentially con-
founding factors were included in multivariate assessment (including tumour size, stage, grade, NPI status, 
vascular invasion status, ER, PgR and HER2 receptor status (all with log-rank statistics of P < 0.001) (Table 2).
In the validation cohort, both low cytoplasmic and low nuclear DARPP-32 expression were significantly asso-
ciated with survival (both P = 0.002) (Fig. 1E,F). Cytoplasmic expression of DARPP-32 remained significantly 
associated with adverse survival (HR: 0.744; 95% CI: 0.577–0.960; P = 0.023) when the potentially confound-
ing factors were included in multivariate assessment (including tumour size, stage, grade, NPI status, vascular 
invasion status ER, PgR and HER2 receptor status (all with log rank statistics of P = 0.001). Nuclear expression 
of DARPP-32 did not remain significantly associated with survival in the validation cohort (HR: 0.786; 95% CI: 
0.608–1.016; P = 0.066).
DARPP-32 expression in ER positive disease. Low expression of DARPP-32 was particularly impor-
tant in patients with ER positive disease. In the discovery cohort, low DARPP-32 cytoplasmic expression was 
significantly associated with adverse survival of ER positive patients (P < 0.001), but not ER negative patients 
(P = 0.099) (Fig. 2A). The same finding was observed when nuclear DARPP-32 expression was assessed, with low 
expression significantly associated with adverse survival of ER positive patients (P < 0.001), but not ER negative 
patients (P = 0.407) (Fig. 2B). In the validation cohort, low cytoplasmic expression of DARPP-32 associated with 
adverse survival of ER positive patients (P < 0.001), but not ER negative patients (P = 0.291) (Fig. 2C). Similar 
findings were for nuclear DARPP-32 expression were observed; with low expression associated with adverse sur-
vival of ER positive patients (P < 0.001), but not ER negative patients (P = 0.679) (Fig. 2D).
DARPP-32 expression in HER2 positive patients treated with trastuzumab. DARPP-32 was 
assessed in a cohort of 112 HER2 positive breast cancer patients treated with adjuvant chemotherapy and tras-
tuzumab. A similar DARPP-32 expression pattern was observed to that in early breast cancer. In this cohort, 
cytoplasmic DARPP-32 had a median H score of 142.9 and ranged from 0 to 300; nuclear DARPP-32 expression 
had a median H score of 45.36 and ranged from 0 to 100. X-tile was used to generate a cut point for analysis based 
on relapse free survival; cytoplasmic DARPP-32 expression had a cut point of 20, with 35.7% of cases (40/112) 
demonstrating low expression, nuclear DARPP-32 expression had a cut point of 5, with 34.8% of cases (39/112) 
demonstrating low expression.
No associations were observed between DARPP-32 expression and clinicopathological criteria in this cohort 
(Table 2). Low nuclear DARPP-32 expression was significantly associated with adverse progression-free survival 
of HER2 positive breast cancer patients treated with trastuzumab (P = 0.031) (Fig. 3A); cytoplasmic DARPP-
32 expression was not associated with progression-free survival (data not shown). Nuclear DARPP-32 expres-
sion did not remain associated with progression-free survival in multivariate Cox regression (HR = 0.387; 95% 
CI = 0.095–1.570; P = 0.184); when tumour size, lymph node status and NPI category were included (with indi-
vidual Kaplan-Meier log rank significance of P = 0.012, P = 0.019 and P = 0.008 respectively).
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PPP1R1B mRNA expression and patient survival. Three PPP1R1B probes were available to assess 
mRNA expression in the METABRIC cohort and expression was categorised using the median gene expres-
sion value to assess for association with patient survival and to perform expression profiling. PPP1R1B probe 
1 (ILMN_1690096) is located within a coding area that corresponds to the N-terminal region of DARPP-32; 
PPP1R1B probe 2 (ILMN_1759012) and PPP1R1B probe 3 (ILMN_2304495) were both located in untrans-
lated regions (5′ and 3′ respectively). Probe 1 and 3 are located in areas found in the sequence for DARPP-32 
(NM_032192), and probe 2 and 3 are located in areas found in the sequence for t-DARPP (NM_181505.3). No 
association was observed between the expression of the probes and disease specific survival. The gene expression 
data was analysed using an artificial neural network approach that uses a machine learning based data mining 
algorithm. A rank order of all the genes was produced based on the minimum average root mean squared error. 
The top 200 transcripts were selected for PPP1R1B probe 1, 2 and 3 and 73 common transcripts were identified 
(Table 3). The transcripts that were common to all three probes included CDC42, DKK1, GRB7, PNMT, and 
GPER amongst others.
All three PPP1R1B probes were further assessed in ER positive patients based on the observed DARPP-32 
protein findings, with a cut point generated in this subgroup of patients using X-tile. PPP1R1B probe 1 expres-
sion was not associated with breast cancer specific survival of ER positive patients; however, low expression of 
PPP1R1B probe 2 and 3 were both associated with adverse survival of ER positive breast cancer patients (P = 0.041 
and P = 0.002 respectively) (Fig. 3B,C).
Discussion
Low nuclear DARPP-32 expression was significantly associated with adverse survival of patients in two inde-
pendent cohorts of patients treated at Nottingham University Hospitals (discovery cohort n = 1352 and vali-
dation cohort n = 1655). Furthermore, low cytoplasmic expression of DARPP-32 was associated with patient 
survival in the validation cohort. The epitope for the antibody used for immunohistochemistry is located within 
amino acids 0–30, meaning that only DARPP-32, and not t-DARPP expression was assessed in this study. There 
are limited reports of DARPP-32 expression and its association with patient survival in cancer. In oesophageal 
squamous cell carcinoma DARPP-32 is expressed after a phase of dysplasia, and low levels of DARPP-32 are asso-
ciated with tumours that progress rapidly33. In colorectal cancer, lower expression of DARPP-32 is associated with 
improved overall survival and disease free survival12, and in non-small cell lung cancer high relative t-DARPP 
Figure 2. DARPP-32 expression association with patient outcome. Kaplan-Meier analysis of breast cancer 
specific survival showing the impact of low (grey line) and high (black line) DARPP-32 expression within the 
cytoplasm in ER positive patients (A) and in the nucleus in ER positive patients (B) in the discovery cohort. 
DARPP-32 expression within the cytoplasm in ER positive patients (C) and in the nucleus in ER positive 
patients (D) in the validation cohort. Significance was determined using the log-rank test. The numbers shown 
below the Kaplan-Meier survival curves are the number of patients at risk at the specified month.
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(in comparison to DARPP-32) is associated with tumour stage34. The expression of DARPP-32 in 230 breast 
cancer patients has been examined previously using N-terminal and C-terminal specific antibodies, to show that 
high N-terminal DARPP-32 expression is associated with adverse patient survival; this differs from the results 
presented here21. It is unclear why opposing results were observed; however, patient demographics, including 
clinicopathological variables, and patient treatment are not available in the previously published study, so cannot 
be directly compared with the current findings.
Interestingly, low DARPP-32 protein expression was particularly important in ER positive patients, in both 
cohorts of patients; there was also a strong association between DARPP-32 expression and ER receptor status. In 
addition to ER status, strong consistent associations were observed between DARPP-32 expression and PgR status 
and triple receptor negative disease in both patient cohorts.
There is accumulating evidence that DARPP-32, in particular t-DARPP, plays a role in response to trastu-
zumab; this study shows that low nuclear expression of DARPP-32 is significantly associated with adverse pro-
gression free survival in 112 HER2 positive patients treated with trastuzumab and adjuvant chemotherapy. This 
is agreement with published in vitro data, that indicates expression of DARPP-32 and t-DARPP expression in 
HER2 positive breast cancer is involved in resistance to trastuzumab22. Expression of t-DARPP has been shown 
to activate IGF-1R signalling in trastuzumab resistant breast cancer cells through increased glycolytic capacity35. 
In addition, DARPP-32 mRNA and protein levels have also been shown to fall in HER2 targeted agent, lapatinib, 
resistant breast cancer cell lines, with a t-DARPP mediated survival advantage observed24.
In models of murine tumourigenesis DARPP-32 expression is expressed in normal mouse tissue and some 
breast tumours, with t-DARPP expressed only within tumours18. It is interesting to hypothesise that the asso-
ciation between patient survival and low expression of DARPP-32 is observed with a corresponding shift to 
increased t-DARPP expression; this will be determined in future studies.
PPP1R1B expression was assessed in the METABRIC cohort, where three probes were available for assess-
ment, probe 1 and 3 located in DARPP-32 and probe 2 and 3 located in t-DARPP. Artificial neural network 
analysis identified a number of genes associated with PPP1R1B expression. Artificial neural network analysis was 
performed using all three PPP1R1B probes and commonalities within the top 200 genes for each probe identified. 
Validation of these associations will be performed as part of future studies. Interestingly, CDC42 was identified 
from this analysis; cdc42 plays a role in filopodia formation and breast cancer cells expressing DARPP-32 have, 
in a study looking at Wnt-5A activation of DARPP-32, been shown to have lower cdc-42 activity17. In addition to 
Figure 3. DARPP-32 expression association with HER2 positive patient outcome. Kaplan-Meier analysis of 
progression-free survival of HER2 positive breast cancer patients treated with adjuvant chemotherapy and 
trastuzumab showing the impact of high (black line) and low (grey line) DARPP-32 protein expression within 
the nucleus (A). Kaplan-Meier analysis of PPP1R1B probe 2 (B) and probe 3 (C) expression in ER positive 
breast cancer patients showing the impact of low expression (grey line) and high expression (black line) and 
breast cancer specific survival. Significance was determined using the log-rank test. The numbers shown below 
the Kaplan-Meier survival curves are the number of patients at risk at the specified month.
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CDC42, Dickkopf-1 (DKK1) was also identified and functions a wnt-5A pathway inhibitor. Furthermore, artificial 
neural network analysis identified an association between PPP1R1B with both GRB7 and PNMT, a link between 
PPP1R1B and these genes has already been described in upper gastrointestinal adenocarcinomas where DNA 
amplification at 17q is often detected (containing PPP1R1B, STARD3, TCAP, PNMT, PERLD1, ERBB2, C17orf37, 
and GRB7)36.
conclusion
This study demonstrates that low DARPP-32 protein expression is associated with shorter survival in two large, 
independent, early stage invasive breast cancer patient cohorts, with a stronger association observed in ER 
positive disease. This finding was also observed at the mRNA level, with low PPP1R1B expression significantly 
associated with shorter survival of ER positive patients in the METABRIC cohort. Furthermore, low DARPP-
32 expression was associated with shorter progression-free survival of HER2 positive patients treated with 
Gene Illumina ID Identity Gene Illumina ID Identity
AFF3 ILMN_1775235 AF4/FMR2 family member 3 NEDD9 ILMN_1726164 Cas scaffolding protein family member 2
AMDHD1 ILMN_1788239 Amidohydrolase domain containing 1 OAT ILMN_1654441 Ornithine aminotransferase
ATP13A5 ILMN_1775285 ATPase 13A5 OAT ILMN_2068747
BBOX 1 ILMN_1734929 Gamma-butyrobetaine hydrolase 1 OBP2B ILMN_1700666 Odorant binding protein 2B
C22orf36 ILMN_1737255 Leucine rich repeat containing 75B ORM2 ILMN_1731785 Orosomucoid 2
CDC42 ILMN_1696041 Cell division cycle 42 PAQR6 ILMN_1689852 Progestin and adipoQ receptor family member 6
CEACAM1 ILMN_1716815 Carcinoembryonic antigen related cell adhesion molecule 1 PDE4B ILMN_1782922 Phosphodiesterase 4B
CITED4 ILMN_1787691 Cbp/p300 interacting transactivator 4 PNMT ILMN_1710027 Phenylethanolamine N-methyltransferase
CPA4 ILMN_1784294 Carboxypeptidase A4 PPP1R1A ILMN_2056606 Protein phosphatase 1 regulatory inhibitor subunit 1A
CRABP1 ILMN_1658040 Cellular reinoic acid binding protein 1 PROM1 ILMN_1786720 Prominin1
CYP4Z1 ILMN_1693594 Cytochrome P450 family 4 subfamily Z member 1 PVRL4 ILMN_1749044 Nectin cell adhesion molecule 4
CYP4Z1 ILMN_1728550 RGMA ILMN_1717636 Repulsive guidance molecule BMP co-receptor A
CYP4Z1 ILMN_2359698 RNF183 ILMN_1692591 Ring finger protein 183
CYP4Z2P ILMN_1702829 Putative inactive cytochrome P450 family member 4Z2 S100A1 ILMN_1653494 S100 calcium binding protein A1
DCD ILMN_1722554 Dercidin S100A13 ILMN_1738707 S100 calcium binding protein A13
DKK1 ILMN_1773337 Dickkopf WNT signalling pathway inhibitor 1 SASH1 ILMN_1712673 SAM and SH3 domin containing 1
ENPP3 ILMN_1749131 Ectonucleotide pyrophosphatase/phosphodiesterase 3 SASH1 ILMN_2185984
FAIM2 ILMN_1803855 Fas apoptotic inhibitory molecule 2 SCGB2A2 ILMN_1723333 Secretoglobulin family 2 A member 2
FAM134B ILMN_1811330 Reticulophagy regulator 1 SLC22A15 ILMN_1730639 Solute carrier family 22 member 15
FAM134B ILMN_2283597 SLC25A18 ILMN_1754864 Solute carrier family 25 member 18
FAM134B ILMN_2387952 SLC5A1 ILMN_1681526 Solute carrier family 5 member 1
FAT ILMN_1754795 FAT atypical cadherin 1 SOX9 ILMN_1805466 SRY box 9
FOLR1 ILMN_2346339 Folate receptor 1 SPINK8 ILMN_1728898 Serine peptidase inhibitor, Kazal type 8
GGT6 ILMN_1788942 Gamma-glutamyltransferase 6 SPRY1 ILMN_1691860 Sprouty RTK signaling antagonist 1
GPER ILMN_1795298 G protein-coupled oestrogen receptor 1 ST6GAL1 ILMN_1756501 ST6 beta-galactosidase alpha-2,6-sialytransferase 1
GRAMD2 ILMN_1661443 GRAM domain containing 2A STAC2 ILMN_1718295 SH3 and cysteine rich domain 2
GRB7 ILMN_1740762 Growth factor receptor bound protein 7 TFAP2B ILMN_1758404 Transcription factor AP-2 beta
HOXA5 ILMN_1753613 Homeobox A5 TFAP2B ILMN_1853592
HSD17B2 ILMN_1808713 Hydroxysteroid 17 beta dehydrogenase 2 TRPV6 ILMN_1674533 Epithelial calcium channel 2
HSH2D ILMN_1788017 Hematopoietic SH2 domain containing TSPAN6 ILMN_1730998 Tetraspannin 6
ICAM1 ILMN_1812226 Intracellular adhesion molecule 1 TTLL4 ILMN_1746846 Tubulin tyrosine ligase like 4
IGSF9 ILMN_1693941 Immunoglobulin superfamily member 9 UBE2E3 ILMN_1669553 Ubiquitin conjugating enzyme E2 E3
KRT7 ILMN_2163723 Keratin 7 UBE2E3 ILMN_2390338
LOC340204 ILMN_1789600 VTCN1 ILMN_1753101 V-set containing T cell activation inhibitor 1
LOC646424 ILMN_1661466 ILMN_1854349_
LOC730525 ILMN_1651610 ILMN_1889752_
MAOB ILMN_1727360 Monoamine oxidase B ILMN_1896906_
MAST4 ILMN_1738438 Microtubule associated Ser/Thr kinase family member 4 ILMN_1902123_
MPZL2 ILMN_1752932 Myelin protein zero like 2 ILMN_1904054_
Table 3. Genes associated with two or more PPP1R1B probes in the METABRIC dataset identified by artificial 
neural network analysis. Those highlighted in bold were associated with expression of all three PPP1R1B probes.
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trastuzumab. This data suggests a potential role for DARPP-32 as a prognostic marker with clinical utility in 
breast cancer, requiring validation on samples from multiple institutions.
compliance with ethical standards. Research involving human participants. Ethical approval for 
the discovery cohort, validation cohort and the HER 2 cohort was granted by Nottingham Research Ethics 
Committee 2, under the title ‘Development of a molecular genetic classification of breast cancer’ (C202313). 
METABRIC samples were collected by five centres in the UK and Canada and were acquired with appropriate 
consent from the respective institutional review boards27. All procedures performed in studies involving human 
participants were in accordance with the ethical standards of the institutional and/or national research committee 
and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. All samples 
collected from Nottingham used in this study were pseudo-anonymised; those collected prior to 2006 did not 
require informed patient consent under the Human Tissue Act, after 2006 informed consent was obtained from 
all individual participants included in the study.
Data availability
The METABRIC data is publically available https://www.ebi.ac.uk/ega/studies/EGAS00000000098. 
Immunohistochemistry datasets analysed during the current study are available from the corresponding author 
on reasonable request.
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